Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Bloom syndrome
Bloom syndrome
Bloom syndrome
Synonyms: BSyn
Synonyms: BSyn
Synonyms: BSyn
Drug discovery
168
papers
On emerging therapies
Rare developmental defect during embryogenesis
Bloom syndrome
Overview
Bloom syndrome is a rare autosomal recessive disorder caused by BLM gene mutations, impairing DNA repair and genomic stability. Key features include severe prenatal/postnatal growth deficiency, photosensitive facial erythema, immune deficiencies, insulin resistance, and a 150-300-fold increased cancer risk. Cancers arise earlier in life (median diagnosis: ~25 years) and include leukemia, lymphoma, and colorectal carcinoma. Multisystem complications involve diabetes, COPD, and infertility. Lifespan is reduced, with median survival ~30 years [1][2][17].
Burden
Cancer: 80% develop cancer by age 40; multiple primaries common (19% with ≥2 cancers) [1][9][14].
Morbidity: Chronic lung disease (25% mortality), diabetes, and recurrent infections drive hospitalizations [10][16][17].
Mortality: Median life expectancy ~30 years; malignancy and respiratory failure are leading causes [2][5][17].
Therapies
Symptom management: Sun protection (SPF 30+, protective clothing), antibiotics for recurrent infections, IV immunoglobulin for hypogammaglobulinemia [3][16][17].
Cancer surveillance: Early/frequent screenings (e.g., Wilms tumor ultrasounds until age 8, annual colonoscopy from age 12-13) [5][7][20].
Therapy modifications: Reduced chemotherapy/radiation doses due to DNA damage hypersensitivity; cautious use of growth hormone [3][6][20].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare hematological diseases, rare immunological diseases, rare neoplastic diseases, rare neurological diseases, rare skin diseases, rare transplant-related disorders
Research Papers
168 drug discovery papers about Bloom syndrome. Recent publications:
168 drug discovery papers about Bloom syndrome. Recent publications:
categories:
Small molecules
cell therapies
2025-06-12 | Successful Haploidentical Haematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated With Monosomy 7/MDS
The data that support the findings of this study are available from the corresponding author upon reasonable request.
2025-04-09 | A Successful Haploidentical Hematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated with Monosomy 7/MDS – Uncharted Territory!
not-yet-known not-yet-known not-yet-known unknown TITLE: A Successful Haploidentical Hematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated with Monosomy 7/MDS – Uncharted Territory!
2024-11-05 | Murine Model of Bloom Syndrome Demonstrates Radiation Survivability Altered By Gut Microbiota
Bloom Syndrome (BSyn) is a rare autosomal recessive disorder caused by biallelic germline variants in BLM, a key genome stabilizer responsible for double-strand break repair. Patients with BSyn commonly present with short stature, elongated facial structure, sun-induced skin rashes, and increased predisposition for developing cancers at young ages, due to genomic instability. Because traditional anti-cancer treatments such as chemotherapy and radiation cause damage to DNA, patients with Bloom Syndrome are prone to severe side effects, such as prolonged hematologic suppression, infections, and secondary cancers. In this study, we used a BSyn mouse model with an extra copy of exon 3, which causes a frameshift and truncates the BLM protein, in order to identify the impact of Blm deficiency in hematopoietic stem cell regeneration. We observed significant differences in 30-day survival after 950 cGy total body irradiation with only 5% of Bloom mice surviving at 30 days compared to 24% of wildtype mice. Peripheral blood counts at day 7 after 950 cGy total body irradiation revealed that Bloom mice had significantly decreased white blood cell and platelet counts compared to wildtype mice, suggesting increased hematotoxicity caused by the Bloom defect. Given increasing evidence that the gut microbiome regulates hematopoiesis, we hypothesized that DNA repair defects seen in BSyn affect gut microbiota, which in turn may regulate hematologic response to DNA damage induced by radiation injury. To first identify any microbiome differences at baseline, we collected fecal samples from Bloom mice and wildtype littermate controls. DNA was extracted and subjected to shotgun sequencing. Data was compared against >127K whole microbial reference genomes using OneCodex. Beta diversity analysis using Bray-Curtis dissimilarity revealed distinct differences between the diversity of Bloom and wildtype gut microbe species at baseline. 2-way ANOVA table analysis identified a significant difference between the relative abundances of the Lachnospiracaea family, specifically the Acetatifactor muris species, in baseline wildtype compared to Bloom gut microbiomes. This established that there are significant baseline gut microbiome differences in Bloom mice compared to wildtype mice and that these differences could be involved in regulating hematopoietic stem cell regeneration after radiation. Interestingly, when irradiated Bloom mice were co-housed with non-irradiated wildtype mice, the Bloom mice had the same median survival as the wildtype group. This led us to hypothesize that introducing the gut microbiota of healthy wildtype mice to Bloom mice could ameliorate effects of lethal irradiation. We then performed fecal microbial transplant (FMT) after lethal irradiation, where Bloom mice were given a suspension of fecal pellets collected from wildtype mice on days 1 and 4 post-radiation, by oral gavage. We found that Bloom mice treated with FMT had a trend toward increased white blood cell count and increased absolute neutrophil count at 7 days post-radiation. Bone marrow examination revealed increased stem and progenitor cell frequency in Bloom mice treated with FMT. Colony forming assay showed statistically significant increased total colonies from Bloom mice treated with FMT compared to untreated Bloom mice, suggesting FMT improved proliferation and differentiation ability of hematopoietic progenitors. Further studies are underway to identify the mechanism by which the gut microbiome may be regulating hematopoietic stem cell regeneration after lethal radiation in Bloom mice.
1984-12-07 | Correction of sister chromatid exchanges in Bloom's syndrome fibroblasts after fusion with cytoplasts from a Chinese hamster cell line.
Cytoplasmic hybrids (cybrids) were prepared by fusion of Bloom's syndrome (BS) fibroblasts with cytoplasts derived from a chloramphenicol (CAP)-resistant cell line of hypoxanthine phosphoribosyl transferase (HPRT)-deficient Chinese hamster wg3h cells to study the role of cytoplasmic and nuclear factors which may involve corrective factor(s) of sister chromatid exchanges (SCEs) of the BS cells. The high rate of SCEs characteristic of the cultured BS fibroblasts was found to be fully corrected in cybrids. This result suggests the existence of a transmissible corrective factor(s) in the cytoplasm of the Chinese hamster cells. Long-term cultures of such cybrids after 3 and 5 weeks of fusion, however, showed a reversion to a high SCE level similar to the parental BS cells, indicating that the corrective factors have not been stable in the cybrid cells.
1984-07-03 | Bloom's syndrome: in vitro correction of the sister chromatid exchange rate by normal cells.
A significant decrease of sister chromatid exchange (SCE) frequencies was observed in Bloom's syndrome(BS) fibroblasts by cocultivation with normal fibroblasts at 5:1, 1:1, 1:5 ratios, and by culture in medium previously used to support normal fibroblasts. On the other hand, the SCE rate of normal fibroblasts was not modified. These results are compared with those from other studies and discussed.
small molecules
2026-05-20 | BLM regulates MALT1-driven NF-κB signalling and is targetable in B-cell malignancies.
Loss of BLM helicase leads to Bloom Syndrome, characterized by genomic instability, cancer predisposition and immunodeficiency. We now show that BLM is essential for the proliferation of cycling B cells and sustains B-cell development by maintaining NF-κB signalling. Hence, in the absence of BLM, the NF-κB pathway is impaired as visualized by the lack of the nuclear translocation of RelA. This action of BLM is due to its binding to the MALT1 promoter (a key positive regulator of NF-κB signalling) and activating its transcription. Reintroduction of MALT1 and constitutively active IKKβ rescues B-cell development in BLM-deficient bone marrow and spleen cells of BLM knockout mice. This indicates that downregulation of MALT1 in BLM-deficient cells is the primary cause of deregulated NF-κB signalling and impaired B-cell development. Interestingly, the pro-proliferative role of BLM can be exploited in the treatment of B-cell malignancies. Here, we demonstrate that depletion of BLM (phenocopied by the inhibition of MALT1) suppresses the progression of lymphoma and leukaemia by inhibiting MALT1-dependent NF-κB signalling and sensitizing malignant B cells to chemotherapy. Together, our findings establish the BLM-MALT1-NF-κB axis as a critical regulator of B-cell development and demonstrate its therapeutic potential in B-cell malignancies. Hence, both upregulation and downregulation of BLM contribute to oncogenesis, underscoring the need to maintain its expression within a tightly controlled threshold.
2026-05-08 | SLX4IP limits replication stress globally and at ALT telomeres.
Faithful DNA replication is essential for genome stability, yet replication forks face constant stress. The Bloom syndrome helicase (BLM) safeguards fork integrity, but excessive BLM activity can itself induce replication stress. We identify SLX4IP as a genome-wide regulator that restrains BLM to maintain replication fork stability. SLX4IP localizes broadly across chromatin with recruitment enhanced under replication stress. Loss of SLX4IP slows replication forks, remodels the replisome, and generates post-replicative single-stranded DNA gaps that are accompanied by elevated nuclear ADP ribose, reflecting compromised replication integrity. These defects are driven by dysregulated BLM activity, establishing SLX4IP as a negative regulator of BLM-dependent replication stress. At ALT telomeres, SLX4IP deficiency triggers ATR signaling, telomere fragility, and accumulation of ALT-associated PML bodies. Here, SLX4IP functions in parallel with FANCM to restrain BLM at ALT telomeres, with co-depletion of SLX4IP and FANCM causing synthetic lethality in ALT-positive cells, a phenotype fully rescued by BLM loss. Together, our results define SLX4IP as a critical genome-wide regulator of replication fork integrity and reveal SLX4IP as a potential vulnerability in ALT-positive cancers.
2026-05-06 | A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death.
Bloom syndrome protein (BLM), a RecQ family DNA helicase, is consistently overexpressed in multiple malignancies, yet its therapeutic potential remains largely unexplored. Herein, we focused on targeting the BLM promoter G-quadruplex (BLM-G4) to inhibit the BLM signaling pathway. We first characterized the parallel BLM-G4 in the BLM promoter region. Subsequently, it is shown for the first time that BLM-G4 recruits phosphorylated signal transducer and activator of transcription 1 (pSTAT1) to activate BLM expression. Importantly, two natural alkaloids, berberine (BER) and coptisine (COP), compete with STAT1 for binding to BLM-G4, thereby significantly suppressing BLM expression in colon cancer cells. The BER/COP-BLM-G4 complex structures were determined using nuclear magnetic resonance experiments, which provide valuable insights for the rational design of next-generation BLM-G4-targeting ligands. Beyond BLM regulation, the conjoint analysis of genome-wide STAT1-CUT&Tag-seq, G4-CUT&Tag-seq, and COP-RNA-seq demonstrated STAT1 as a general G4-binding transcription factor and COP as a pan-genomic G4 stabilizer. Furthermore, BER/COP exhibited a pronounced synergistic effect with olaparib in inducing colon cancer cell death by disrupting DNA repair pathways and intensifying DNA damage. Collectively, our findings reveal a novel epigenetic mechanism of BLM gene upregulation mediated by BLM-G4-STAT1 interaction and suggest that the combination therapy of G4 stabilizers with poly(ADP) ribose polymerase (PARP) inhibitors is a promising strategy for treating complex cancers.
2026-04-29 | Unraveling the Molecular Mechanisms and Genomic Regions of Post-Mitotic DNA Synthesis
The maintenance of genome integrity is essential for cellular survival, yet it is constantly challenged by diverse endogenous and exogenous sources of stress. Replication stress is a major driver of genome instability and a hallmark of tumorigenesis. Difficult-to-replicate genomic regions, such as telomeres, are particularly vulnerable to replication stress and often remain under-replicated by the end of S-phase. Consequently, DNA synthesis beyond S-phase has emerged as a crucial safeguard to complete replication at these loci. Under-replicated regions and replication stress-induced DNA lesions may escape cell cycle checkpoint surveillance and persist into mitosis, where they can be repaired by mitotic DNA synthesis (MiDAS), or are transmitted to the next cell generation. In G1-phase of newly born daughter cells, these inherited replication stress-derived DNA lesions are bound and protected by the heterotrimeric replication protein A (RPA) complex and undergo post-mitotic DNA synthesis (post-MiDAS), especially in cancer cells that employ alternative lengthening of telomeres (ALT). However, the genomic regions that undergo post-MiDAS beyond telomeres and the underlying molecular mechanisms remained poorly understood. Here, we demonstrate that telomeres and centromeres, which are highly repetitive and late-replicating regions of the human genome, undergo post-MiDAS in response to replication stress in the previous cell cycle and frequently cluster together at post-MiDAS sites. We further show that telomeres form clusters within promyelocytic leukemia (PML) nuclear bodies during post-MiDAS, which is associated with SUMOylation and the recruitment of the Bloom syndrome helicase BLM. Through a targeted siRNA screen in G1-synchronized cells, we reveal that proteins implicated in ALT, MiDAS, and translesion DNA synthesis (TLS) also act in post-MiDAS in G1. Moreover, using complementary quantitative proteomics approaches, we define the interactome of the RPA complex in G1-phase and uncover novel candidate regulators of post-MiDAS in a proteome-wide manner. Among these, we identify the ubiquitin ligase anaphase promoting complex/cyclosome (APC/C). We show that the APC/C, together with its co-activator CDH1, restrains excessive post-MiDAS, potentially by regulating TOPBP1 protein levels and thereby controlling non-canonical TOPBP1-mediated ATR activation in G1. Finally, we demonstrate that the depletion of CDH1 selectively impairs the survival of ALT-positive cancer cells, revealing post-MiDAS as a potential therapeutic vulnerability. $\textit{Full-text embargoed until: 2027-03-18}$
2026-04-15 | A dual role for cGAS in shaping cellular and organismal responses to genomic instability.
Mutations in DNA damage repair (DDR) genes lead to genomic instability, driving a range of degenerative syndromes. In addition to promoting mutation accumulation, unrepaired DNA damage can leak into the cytosol and activate innate immune-sensing pathways, particularly the cGAS-STING axis. However, the extent to which cGAS causally contributes to organismal pathology in DDR syndromes in vivo remains unresolved. Here, we genetically model ataxia telangiectasia (A-T) and Bloom syndrome in the short-lived turquoise killifish (Nothobranchius furzeri) and demonstrate that genetic disruption of cgas in the A-T model partially ameliorates germline failure, hepatic senescence, and cerebellar neuroinflammation. Unexpectedly, cgas loss also reversed cellular hallmarks of genome instability, including reduced micronuclei, improved telomere integrity, and restored H3K9me3-marked heterochromatin landscape, consistent with STING-independent nuclear functions of cGAS that influence DNA repair and chromatin. Together, these data identify cGAS as a context-dependent amplifier of DDR pathology acting through canonical inflammatory signaling and noncanonical nuclear mechanisms that shape genome stability. Accordingly, our findings support pharmacological cGAS inhibition as a potential strategy for DDR syndromes in settings of chronic DNA damage while highlighting that cgas loss in an otherwise naive background exacerbates pathology and genomic instability, underscoring its essential role in normal physiology.
proteins
2025-02-25 | Phosphorylated BLM peptide acts as an agonist for DNA damage response.
Upon exposure to ionizing irradiation, the MRE11-RAD50-NBS1 complex potentiates the recruitment of ATM (ataxia-telangiectasia mutated) kinase to the double-strand breaks. We show that the lack of BLM causes a decrease in the autophosphorylation of ATM in mice mammary glands, which have lost one or both copies of BLM. In isogenic human cells, the DNA damage response (DDR) pathway was dampened in the absence of BLM, which negatively affected the recruitment of DDR factors onto the chromatin, thereby indicating a direct role of BLM in augmenting DDR. Mechanistically, this was due to the BLM-dependent dissociation of inactive ATM dimers into active monomers. Fragmentation analysis of BLM followed by kinase assays revealed a 20-mer BLM peptide (91-110 aa), sufficient to enhance ATM-dependent p53 phosphorylation. ATM-mediated phosphorylation of BLM at Thr99 within BLM (91-110) peptide enhanced ATM kinase activity due to its interaction with NBS1 and causing ATM monomerization. Delivery of phosphomimetic T99E counterpart of BLM (91-110 aa) peptide led to ATM activation followed by restoration of the DDR even in the absence of ionizing irradiation (both in cells and in BLM knockout mice), indicating its role as a DDR agonist, which can be potentially used to prevent the initiation of neoplastic transformation.
2025-01-15 | Synergistic protection of nascent DNA at stalled forks by MSANTD4 and BRCA1/2-RAD51.
The regressed arms of reversed replication forks exhibit structural similarities to one-ended double-stranded breaks and need to be protected against uncontrolled nucleolytic degradation. Here, we identify MSANTD4 (Myb/SANT-like DNA-binding domain-containing protein 4), a functionally uncharacterized protein that uniquely counters the replication protein A (RPA)-Bloom (BLM)/Werner syndrome helicase (WRN)-DNA replication helicase/nuclease 2 (DNA2) complex to safeguard reversed replication forks from detrimental degradation, independently of the breast cancer susceptibility proteins (BRCA1/2)-DNA repair protein RAD51 pathway. MSANTD4 specifically interacts with the junctions between single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in DNA substrates harboring a 3' overhang, which resemble the structural features of regressed arms processed by WRN-DNA2. This DNA-binding capability allows MSANTD4 to accumulate at reversed forks, strategically antagonizing the RPA-BLM/WRN-DNA2 complex by impeding its access to the ssDNA-dsDNA junction of the regressed arms. Loss of MSANTD4 exacerbates genome instability induced by replication stress in BRCA1/2-deficient cells. Our findings unveil a collaborative defense mechanism orchestrated by MSANTD4 and BRCA1/2-RAD51, effectively counteracting nucleolytic attacks on the regressed arms and synergistically preserving the integrity of reversed forks.
2023-10-12 | Modified iPOND revealed the role of mutant p53 in promoting helicase function and telomere maintenance
The G-rich DNA, such as telomere, tends to form G-quadruplex (G4) structure, which slows down the replication fork progression, induces replication stress, and becomes the chromosome fragile sites.Here we described a molecular strategy that cells developed to overcome the DNA replication stress via DNA helicase regulation.The p53N236S (p53S) mutation has been found in the Werner syndrome mouse embryo fibroblast (MEFs) escaped from senescence, could be the driving force for cell escaping senescence.We revealed that the p53S could transcriptionally up-regulate DNA helicases expression, including Wrn, Blm, Timeless, Ddx, Mcm, Gins, Fanc, as well as telomere specific proteins Terf1, Pot1, through which p53S promoted the unwinding of G4 structures, and protected the cells from DNA replication stress induced by G4 stabilizer.By modified iPOND (isolation of proteins on nascent DNA) assay and telomere assay, we demonstrated that the p53S could promote the recruitment of those helicases to the DNA replication forks, facilitated the maintenance of telomere, and prevent the telomere dysfunction induced by G4 stabilizer.Interestingly, we did not observe the function of promoting G4 resolving and facilitating telomere lengthening in the cells with Li-Fraumeni Syndrome mutation-p53R172H (p53H), which suggests that this is the specific gain of function for p53S.Together our data suggest that the p53S could gain the new function of releasing the replication stress via regulating the helicase function and G4 structure, which benefits telomere lengthening.This strategy could be applied to the treatment of diseases caused by telomere replication stress.
2023-03-30 | Data from BLM Helicase Facilitates Mus81 Endonuclease Activity in Human Cells
<div>Abstract<p>Bloom syndrome is a rare, autosomal recessive inherited disorder in humans. The product of the Bloom syndrome mutated gene, designated BLM, is a member of the RecQ helicase family. BLM has been proposed to function at the interface of replication and recombination, and to facilitate the repair of DNA damage. Here, we report <i>in vivo</i> physical interaction and colocalization of BLM and a DNA structure–specific endonuclease, Mus81, at sites of stalled replication forks outside the promyelocytic leukemia nuclear bodies during the S-phase arrest of the cell cycle. Amino acids 125 to 244 of Mus81 interact with the C-terminal region (amino acids 1,007-1,417) of BLM. Whereas Mus81 does not have any effect on the helicase activity of BLM, BLM can stimulate Mus81 endonuclease activity on the nicked Holliday junctions and 3′ flap. This stimulation is due to enhanced binding of Mus81 to the DNA substrates. These data suggest a new function of BLM in cooperating with Mus81 during processing and restoration of stalled replication forks.</p></div>
2023-03-27 | KNO1‐mediated autophagic degradation of the Bloom syndrome complex component RMI1 promotes homologous recombination
Abstract Homologous recombination (HR) is a key DNA damage repair pathway that is tightly adjusted to the state of a cell. A central regulator of homologous recombination is the conserved helicase‐containing Bloom syndrome complex, renowned for its crucial role in maintaining genome integrity. Here, we show that in Arabidopsis thaliana , Bloom complex activity is controlled by selective autophagy. We find that the recently identified DNA damage regulator KNO1 facilitates K63‐linked ubiquitination of RMI1, a structural component of the complex, thereby triggering RMI1 autophagic degradation and resulting in increased homologous recombination. Conversely, reduced autophagic activity makes plants hypersensitive to DNA damage. KNO1 itself is also controlled at the level of proteolysis, in this case mediated by the ubiquitin–proteasome system, becoming stabilized upon DNA damage via two redundantly acting deubiquitinases, UBP12 and UBP13. These findings uncover a regulatory cascade of selective and interconnected protein degradation steps resulting in a fine‐tuned HR response upon DNA damage.
gene therapies
2026-06-24 | Early-Onset Colorectal and Gastric Adenocarcinomas in a Patient With a Heterozygous BLM p.E1317K Variant of Uncertain Significance
Early-onset gastrointestinal malignancies may raise concerns for hereditary cancer susceptibility, although interpretation of rare germline variants identified through multigene testing remains challenging. We describe the case of a male patient diagnosed with stage IIIB mismatch repair-proficient sigmoid adenocarcinoma at age 29 who subsequently developed a poorly differentiated gastric adenocarcinoma five years later. Germline testing identified a heterozygous BLM p.E1317K variant of uncertain significance (VUS) and no other pathogenic germline alterations. Both tumors demonstrated microsatellite-stable, mismatch repair-proficient disease with low tumor mutational burden, and the patient’s family history was notable for gastric cancer in his father, collectively raising concern for an underlying cancer predisposition. Although Bloom syndrome is associated with biallelic pathogenic BLM variants, the oncologic significance of heterozygous BLM alterations remains incompletely defined. This report highlights the interpretive challenges surrounding rare germline variants in patients with multiple early-onset gastrointestinal malignancies and underscores the need for further investigation into the potential role of selected heterozygous BLM variants in cancer susceptibility.
2025-11-08 | The Relationship Between Insulin Resistance and Cancer in Humans.
An independent association between insulin resistance and cancer has been consistently reported in humans. Patients with cancer display insulin resistance or its clinical manifestations, and this metabolic adaptation precedes the clinical diagnosis of cancer. Insulin resistance in cancer patients is associated with a metabolic switch from oxidative metabolism toward glycolysis that spares oxygen to be used in anabolic processes and facilitates the fast production of energy and intermediate metabolites required for the rapid proliferation of cancer cells. In malignant cells, glucose consumption via glycolysis occurs under normoxic conditions (aerobic glycolysis). Pathogenic mechanisms underlying insulin resistance in cancer patients include hypoxia-inducible factor-1 upregulation and overproduction of cytokines, such as interferon, interleukin-6, interleukin-18, and interleukin-1β. Deficit of 2-oxoglutarate (α-ketoglutarate) has been detected in cancer cells and may facilitate hypoxia-inducible factor-1 assembly and activity. Overproduction of cytokines in cancer patients follows activation of the immune system by abnormal nucleic acid variants. Anomalous DNA or RNA structures are recognized by immune sensors and stimulate signaling pathways that ultimately increase cytokine production. Likewise, interferon overproduction occurs in congenital disorders that feature ineffectively repaired DNA lesions, such as Werner syndrome, Bloom syndrome, mutations in DNA polymerase-δ1, and ataxia telangiectasia. These diseases cause simultaneous insulin resistance and a high tendency to develop cancer, highlighting the relationship between the two processes. Defectively repaired DNA injury endangers genomic integrity, predisposing to cancer, and activates the immune system to increase interferon production and subsequent insulin resistance. Hypoxia-inducible factor-1 and cytokines induce insulin resistance by suppressing peroxisome proliferator-activated-γ in the subcutaneous adipose tissue.
2025-09-01 | The First Report on BLM Gene Mutations in Iranian Patients with Different Phenotypes of Bloom Syndrome: Identifying Two Mutations and a Literature Review on BLM Gene Mutations
Bloom syndrome (BS), also called congenital telangiectatic erythema, is a rare autosomal recessive inherited disorder characterized by genomic instability and predisposition to the development of all types of cancer. Besides, additional presentations have been observed in BS. Herein, we investigated the clinical and genetic aspects ofeight patients withBS in three unrelated Iranian families that exhibit less common symptoms like intellectual disability and polydactyly. After the thorough clinical examinations, whole-exome sequencing (WES) was performed. Following the detection of candidate variants, the familialco-segregation analysis was carried out by PCR-based Sanger sequencing. Meanwhile, a literature review was carried out by utilizing databases to compile information on BLM gene mutations from 2007 to the present. We identified two pathogenic nonsense mutations in the BLM gene in the studied families with the homozygous state. The first one, c.3415C>T (p.Arg1139Ter) mutation, was detected in the 5 patients from family 1 and one patient from family 3. The second one was c.2695C>T (p.Arg899Ter) mutation identified in the two patients from family 2. All unaffected parents were identified with the heterozygous state for the detected mutations in their affected offspring. Through our research in various articles, we gathered twelve different mutations in 17 BS patients from 2007 to the present. Mutation identification and presenting clinical manifestation of the rare disorder make it much easier and faster to diagnose this syndrome from other similar disorders. It also helps with carrier detection, as well as, prenatal diagnosis of bloom syndrome in high-risk families.
2025-03-01 | Establishment of Preclinical Trial of Lentiviral Gene Transfer to Prevent Bloom Syndrome-Related Hematological Malignancy
Bloom syndrome is a rare hereditary DNA repair disorder associated with a high risk of cancer. Patients with Bloom syndrome have a markedly increased risk of developing various cancers, particularly hematological malignancies, making cancer the leading cause of death in these individuals. Therefore, we hypothesized that the prevention of cancer could be a key point for these patients. This review focuses on designing a preclinical study exploring the potential of gene therapy to address this significant clinical challenge. Three issues were established for this preclinical study, and research is ongoing to solve these issues. The first was the development of an envelope-modified lentivirus designed to treat DNA repair disorders. This lentivirus has been engineered to effectively deliver therapeutic genes to cells affected by Bloom syndrome, and cytokine stimulation induces apoptosis in hematopoietic stem cells (HSCs). Second, we demonstrated that lentivirus-mediated gene transfer corrects the expression and function of BLM gene in bone marrow cells derived from a Bloom syndrome mouse model. These experiments indicated that the therapeutic gene delivered by the lentivirus can correct cellular defects associated with Bloom syndrome, thereby restoring normal cell function. Finally, we investigated the ability of gene therapy to prevent the development of radiation-induced tumors in BLM mice. By detailing the development and testing of this innovative gene therapy, this review demonstrated the potential of such treatments to transform the clinical management of DNA repair disorders, which could be translated into improved survival and quality of life in patients with Bloom syndrome.
2023-03-01 | Protocol for a high titer of BaEV-Rless pseudotyped lentiviral vector: Focus on syncytium formation and detachment.
The development of hematopoietic stem cell (HSCs) gene therapy for DNA repair disorders, such as Fanconi anemia and Bloom syndrome, is challenging because of the induction of HSCs apoptosis by cytokine stimulation. Although the Baboon envelope pseudotyped lentiviral vector (BaEV-Rless-LV) has been reported as a non-stimulatory gene transfer tool, the virus titer of BaEV-Rless-LV is too low for use in clinical applications. Transfected 293 T cells with helper plasmids, including the BaEV-Rless plasmid, showed morphological changes, such as syncytium formation and detachment. To establish a novel protocol for producing a high titer of BaEV-Rless-LV, we optimized three aspects of a basic virus production protocol by focusing on modifying culture conditions and the use of reagents: the virus titer increased 3-fold when the amount of BaEV-Rless plasmid was increased 1.2-fold; the highest titer was obtained when the viral supernatant was harvested at 48-h post-transfection, despite complete syncytium formation and detachment of the 293 T cells; and the use of poly-L-lysine-coated culture plates to enhance the adhesion and proliferation of 293 T cells and prevent detachment doubled the titer. Collectively, our novel protocol resulted in a 10-fold titer increase compared to the basic protocol and may be useful in clinical applications for treating DNA repair disorders.
other
2025-02-18 | BLM knockdown promotes cells autophagy via p53-AMPK-mTOR pathway in triple negative breast cancer cells.
This study investigated the function of the Bloom syndrome RecQ helicase-like gene (BLM) in triple-negative breast cancer (TNBC). The expression levels of BLM in breast cancer cells were assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemical analysis. Cell proliferation, apoptosis, migration, and invasion were evaluated using the CCK-8 assay, clonogenic assay, flow cytometry, wound healing assay, and Transwell assay, respectively. Autophagosomes were observed via transmission electron microscopy (TEM). The expression levels of LC3B, Beclin1, and p62 were also measured. A murine xenograft model was employed to examine the impact of BLM on TNBC tumor growth, with tumor weight and volume recorded. Hematoxylin and eosin (H&E) staining and immunohistochemistry were utilized to assess pathological changes and Ki67 expression in tumor tissues. Additionally, Western blotting analysis was conducted to determine the expression of p53, AMPK, phosphorylated AMPK (p-AMPK), mTOR, and phosphorylated mTOR (p-mTOR). The expression of BLM was elevated in BT549 cells compared to normal cells. Following BLM knockdown, BT549 cell proliferation was significantly reduced, while apoptosis was enhanced. The migration rate of cells in the siBLM group was markedly decreased, as were the invasion and metastasis rates. TEM results indicated an increased presence of autophagosomes in the siBLM group, with significantly elevated expression levels of LC3B and Beclin1, and a decreased expression level of p62. Tumor volume and weight in the shBLM group were significantly lower than those in the shCtrl group. The number of intratumoral cells decreased, with most exhibiting nucleolysis or disintegration. Ki67 expression in the tumor tissue was also notably reduced. Additionally, the expression levels of p-mTOR, p-AMPK, and P53 proteins in the shBLM group were decreased. The knockdown of BLM significantly inhibited cell proliferation, migration, and invasion, while promoting apoptosis. This effect may be mediated through the regulation of the p53-AMPK-mTOR pathway.
2008-04-02 | Competition between the DNA unwinding and strand pairing activities of the Werner and Bloom syndrome proteins.
The premature aging and cancer-prone Werner and Bloom syndromes are caused by defects in the RecQ helicase enzymes WRN and BLM, respectively. Recently, both WRN and BLM (as well as several other RecQ members) have been shown to possess a strand annealing activity in addition to the requisite DNA unwinding activity. Since an annealing function would appear to directly oppose the action of a helicase, we have examined in this study the dynamic equilibrium between unwinding and annealing mediated by either WRN or BLM. Our investigation into the competition between annealing and unwinding demonstrates that, under standard reaction conditions, WRN- or BLM-mediated annealing can partially or completely mask unwinding as measured in standard helicase assays. Several strategies were employed to suppress the annealing activity so that the actual strength of WRN- or BLM-dependent unwinding could be more accurately assessed. Interestingly, if a DNA oligomer complementary to one strand of the DNA substrate to be unwound is added during the helicase reaction, both WRN and BLM unwinding is enhanced, presumably by preventing protein-mediated re-annealing. This strategy allowed measurement of WRN-catalyzed unwinding of long (80 base pair) duplex regions and fully complementary, blunt-ended duplexes, both of which were otherwise quite refractory to the helicase activity of WRN. Similarly, the addition of trap strand stimulated the ability of BLM to unwind long and blunt-ended duplexes. The stimulatory effect of the human replication protein A (hRPA, the eukaryotic single-stranded DNA binding protein) on both WRN- and BLM-dependent unwinding was also re-examined in light of its possible role in preventing re-annealing. Our results show that hRPA influences the outcome of WRN and BLM helicase assays by both inhibiting re-annealing and directly promoting unwinding, with the larger contribution from the latter mechanism. These findings indicate that measurements of unwinding by WRN, BLM, and probably other RecQ helicases are complicated by their annealing properties. Thus, WRN- and BLM-dependent unwinding activities are significantly stronger than previously believed. Since this broadens the range of potential physiological substrates for WRN and BLM, our findings have relevance for understanding their functions in vitro and in vivo.
2006-02-07 | Enhanced gene targeting efficiency by siRNA that silences the expression of the Bloom syndrome gene in human cells
Gene targeting via homologous recombination is a powerful tool for studying gene function, but the targeting efficiency in human cell lines is too low for generating knockout mutants. Several cell lines null for the gene responsible for Bloom syndrome, BLM , have shown elevated targeting efficiencies. Therefore, we reasoned that gene targeting would be enhanced by transient suppression of BLM expression by RNA interference. To test this, we constructed a gene correction assay system to measure gene targeting frequencies using a disrupted hypoxanthine phosphoribosyltransferase ( HPRT ) locus in the human HT1080 cell line, and examined the effect of small interfering RNA (siRNA) for BLM on gene targeting. When HPRT ‐null cells pretreated with BLM siRNA were co‐transfected with the siRNA and a gene correction vector, the gene targeting frequency was elevated three‐fold, while the random integration frequency was marginally affected. Remarkably, in BLM heterozygous (+/–) cells derived from HPRT ‐null cells, the BLM siRNA treatment gave more than five‐fold higher targeting frequencies, even with one‐tenth the amount of BLM siRNA used for BLM +/+ cells. Furthermore, in the human pre‐B cell line Nalm‐6, the siRNA treatment enhanced gene targeting 6.3‐fold and > 5.8‐fold at the HPRT and adenine phosphoribosyltransferase ( APRT ) loci, respectively. These results indicate that transient suppression of BLM expression by siRNA stimulates gene targeting in human cells, facilitating a further improvement of gene targeting protocols for human cell lines.
2005-06-28 | BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.
Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLM(Cin/+), transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.
cell therapies
2025-06-12 | Successful Haploidentical Haematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated With Monosomy 7/MDS
The data that support the findings of this study are available from the corresponding author upon reasonable request.
2025-04-09 | A Successful Haploidentical Hematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated with Monosomy 7/MDS – Uncharted Territory!
not-yet-known not-yet-known not-yet-known unknown TITLE: A Successful Haploidentical Hematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated with Monosomy 7/MDS – Uncharted Territory!
2024-11-05 | Murine Model of Bloom Syndrome Demonstrates Radiation Survivability Altered By Gut Microbiota
Bloom Syndrome (BSyn) is a rare autosomal recessive disorder caused by biallelic germline variants in BLM, a key genome stabilizer responsible for double-strand break repair. Patients with BSyn commonly present with short stature, elongated facial structure, sun-induced skin rashes, and increased predisposition for developing cancers at young ages, due to genomic instability. Because traditional anti-cancer treatments such as chemotherapy and radiation cause damage to DNA, patients with Bloom Syndrome are prone to severe side effects, such as prolonged hematologic suppression, infections, and secondary cancers. In this study, we used a BSyn mouse model with an extra copy of exon 3, which causes a frameshift and truncates the BLM protein, in order to identify the impact of Blm deficiency in hematopoietic stem cell regeneration. We observed significant differences in 30-day survival after 950 cGy total body irradiation with only 5% of Bloom mice surviving at 30 days compared to 24% of wildtype mice. Peripheral blood counts at day 7 after 950 cGy total body irradiation revealed that Bloom mice had significantly decreased white blood cell and platelet counts compared to wildtype mice, suggesting increased hematotoxicity caused by the Bloom defect. Given increasing evidence that the gut microbiome regulates hematopoiesis, we hypothesized that DNA repair defects seen in BSyn affect gut microbiota, which in turn may regulate hematologic response to DNA damage induced by radiation injury. To first identify any microbiome differences at baseline, we collected fecal samples from Bloom mice and wildtype littermate controls. DNA was extracted and subjected to shotgun sequencing. Data was compared against >127K whole microbial reference genomes using OneCodex. Beta diversity analysis using Bray-Curtis dissimilarity revealed distinct differences between the diversity of Bloom and wildtype gut microbe species at baseline. 2-way ANOVA table analysis identified a significant difference between the relative abundances of the Lachnospiracaea family, specifically the Acetatifactor muris species, in baseline wildtype compared to Bloom gut microbiomes. This established that there are significant baseline gut microbiome differences in Bloom mice compared to wildtype mice and that these differences could be involved in regulating hematopoietic stem cell regeneration after radiation. Interestingly, when irradiated Bloom mice were co-housed with non-irradiated wildtype mice, the Bloom mice had the same median survival as the wildtype group. This led us to hypothesize that introducing the gut microbiota of healthy wildtype mice to Bloom mice could ameliorate effects of lethal irradiation. We then performed fecal microbial transplant (FMT) after lethal irradiation, where Bloom mice were given a suspension of fecal pellets collected from wildtype mice on days 1 and 4 post-radiation, by oral gavage. We found that Bloom mice treated with FMT had a trend toward increased white blood cell count and increased absolute neutrophil count at 7 days post-radiation. Bone marrow examination revealed increased stem and progenitor cell frequency in Bloom mice treated with FMT. Colony forming assay showed statistically significant increased total colonies from Bloom mice treated with FMT compared to untreated Bloom mice, suggesting FMT improved proliferation and differentiation ability of hematopoietic progenitors. Further studies are underway to identify the mechanism by which the gut microbiome may be regulating hematopoietic stem cell regeneration after lethal radiation in Bloom mice.
1984-12-07 | Correction of sister chromatid exchanges in Bloom's syndrome fibroblasts after fusion with cytoplasts from a Chinese hamster cell line.
Cytoplasmic hybrids (cybrids) were prepared by fusion of Bloom's syndrome (BS) fibroblasts with cytoplasts derived from a chloramphenicol (CAP)-resistant cell line of hypoxanthine phosphoribosyl transferase (HPRT)-deficient Chinese hamster wg3h cells to study the role of cytoplasmic and nuclear factors which may involve corrective factor(s) of sister chromatid exchanges (SCEs) of the BS cells. The high rate of SCEs characteristic of the cultured BS fibroblasts was found to be fully corrected in cybrids. This result suggests the existence of a transmissible corrective factor(s) in the cytoplasm of the Chinese hamster cells. Long-term cultures of such cybrids after 3 and 5 weeks of fusion, however, showed a reversion to a high SCE level similar to the parental BS cells, indicating that the corrective factors have not been stable in the cybrid cells.
1984-07-03 | Bloom's syndrome: in vitro correction of the sister chromatid exchange rate by normal cells.
A significant decrease of sister chromatid exchange (SCE) frequencies was observed in Bloom's syndrome(BS) fibroblasts by cocultivation with normal fibroblasts at 5:1, 1:1, 1:5 ratios, and by culture in medium previously used to support normal fibroblasts. On the other hand, the SCE rate of normal fibroblasts was not modified. These results are compared with those from other studies and discussed.
small molecules
2026-05-20 | BLM regulates MALT1-driven NF-κB signalling and is targetable in B-cell malignancies.
Loss of BLM helicase leads to Bloom Syndrome, characterized by genomic instability, cancer predisposition and immunodeficiency. We now show that BLM is essential for the proliferation of cycling B cells and sustains B-cell development by maintaining NF-κB signalling. Hence, in the absence of BLM, the NF-κB pathway is impaired as visualized by the lack of the nuclear translocation of RelA. This action of BLM is due to its binding to the MALT1 promoter (a key positive regulator of NF-κB signalling) and activating its transcription. Reintroduction of MALT1 and constitutively active IKKβ rescues B-cell development in BLM-deficient bone marrow and spleen cells of BLM knockout mice. This indicates that downregulation of MALT1 in BLM-deficient cells is the primary cause of deregulated NF-κB signalling and impaired B-cell development. Interestingly, the pro-proliferative role of BLM can be exploited in the treatment of B-cell malignancies. Here, we demonstrate that depletion of BLM (phenocopied by the inhibition of MALT1) suppresses the progression of lymphoma and leukaemia by inhibiting MALT1-dependent NF-κB signalling and sensitizing malignant B cells to chemotherapy. Together, our findings establish the BLM-MALT1-NF-κB axis as a critical regulator of B-cell development and demonstrate its therapeutic potential in B-cell malignancies. Hence, both upregulation and downregulation of BLM contribute to oncogenesis, underscoring the need to maintain its expression within a tightly controlled threshold.
2026-05-08 | SLX4IP limits replication stress globally and at ALT telomeres.
Faithful DNA replication is essential for genome stability, yet replication forks face constant stress. The Bloom syndrome helicase (BLM) safeguards fork integrity, but excessive BLM activity can itself induce replication stress. We identify SLX4IP as a genome-wide regulator that restrains BLM to maintain replication fork stability. SLX4IP localizes broadly across chromatin with recruitment enhanced under replication stress. Loss of SLX4IP slows replication forks, remodels the replisome, and generates post-replicative single-stranded DNA gaps that are accompanied by elevated nuclear ADP ribose, reflecting compromised replication integrity. These defects are driven by dysregulated BLM activity, establishing SLX4IP as a negative regulator of BLM-dependent replication stress. At ALT telomeres, SLX4IP deficiency triggers ATR signaling, telomere fragility, and accumulation of ALT-associated PML bodies. Here, SLX4IP functions in parallel with FANCM to restrain BLM at ALT telomeres, with co-depletion of SLX4IP and FANCM causing synthetic lethality in ALT-positive cells, a phenotype fully rescued by BLM loss. Together, our results define SLX4IP as a critical genome-wide regulator of replication fork integrity and reveal SLX4IP as a potential vulnerability in ALT-positive cancers.
2026-05-06 | A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death.
Bloom syndrome protein (BLM), a RecQ family DNA helicase, is consistently overexpressed in multiple malignancies, yet its therapeutic potential remains largely unexplored. Herein, we focused on targeting the BLM promoter G-quadruplex (BLM-G4) to inhibit the BLM signaling pathway. We first characterized the parallel BLM-G4 in the BLM promoter region. Subsequently, it is shown for the first time that BLM-G4 recruits phosphorylated signal transducer and activator of transcription 1 (pSTAT1) to activate BLM expression. Importantly, two natural alkaloids, berberine (BER) and coptisine (COP), compete with STAT1 for binding to BLM-G4, thereby significantly suppressing BLM expression in colon cancer cells. The BER/COP-BLM-G4 complex structures were determined using nuclear magnetic resonance experiments, which provide valuable insights for the rational design of next-generation BLM-G4-targeting ligands. Beyond BLM regulation, the conjoint analysis of genome-wide STAT1-CUT&Tag-seq, G4-CUT&Tag-seq, and COP-RNA-seq demonstrated STAT1 as a general G4-binding transcription factor and COP as a pan-genomic G4 stabilizer. Furthermore, BER/COP exhibited a pronounced synergistic effect with olaparib in inducing colon cancer cell death by disrupting DNA repair pathways and intensifying DNA damage. Collectively, our findings reveal a novel epigenetic mechanism of BLM gene upregulation mediated by BLM-G4-STAT1 interaction and suggest that the combination therapy of G4 stabilizers with poly(ADP) ribose polymerase (PARP) inhibitors is a promising strategy for treating complex cancers.
2026-04-29 | Unraveling the Molecular Mechanisms and Genomic Regions of Post-Mitotic DNA Synthesis
The maintenance of genome integrity is essential for cellular survival, yet it is constantly challenged by diverse endogenous and exogenous sources of stress. Replication stress is a major driver of genome instability and a hallmark of tumorigenesis. Difficult-to-replicate genomic regions, such as telomeres, are particularly vulnerable to replication stress and often remain under-replicated by the end of S-phase. Consequently, DNA synthesis beyond S-phase has emerged as a crucial safeguard to complete replication at these loci. Under-replicated regions and replication stress-induced DNA lesions may escape cell cycle checkpoint surveillance and persist into mitosis, where they can be repaired by mitotic DNA synthesis (MiDAS), or are transmitted to the next cell generation. In G1-phase of newly born daughter cells, these inherited replication stress-derived DNA lesions are bound and protected by the heterotrimeric replication protein A (RPA) complex and undergo post-mitotic DNA synthesis (post-MiDAS), especially in cancer cells that employ alternative lengthening of telomeres (ALT). However, the genomic regions that undergo post-MiDAS beyond telomeres and the underlying molecular mechanisms remained poorly understood. Here, we demonstrate that telomeres and centromeres, which are highly repetitive and late-replicating regions of the human genome, undergo post-MiDAS in response to replication stress in the previous cell cycle and frequently cluster together at post-MiDAS sites. We further show that telomeres form clusters within promyelocytic leukemia (PML) nuclear bodies during post-MiDAS, which is associated with SUMOylation and the recruitment of the Bloom syndrome helicase BLM. Through a targeted siRNA screen in G1-synchronized cells, we reveal that proteins implicated in ALT, MiDAS, and translesion DNA synthesis (TLS) also act in post-MiDAS in G1. Moreover, using complementary quantitative proteomics approaches, we define the interactome of the RPA complex in G1-phase and uncover novel candidate regulators of post-MiDAS in a proteome-wide manner. Among these, we identify the ubiquitin ligase anaphase promoting complex/cyclosome (APC/C). We show that the APC/C, together with its co-activator CDH1, restrains excessive post-MiDAS, potentially by regulating TOPBP1 protein levels and thereby controlling non-canonical TOPBP1-mediated ATR activation in G1. Finally, we demonstrate that the depletion of CDH1 selectively impairs the survival of ALT-positive cancer cells, revealing post-MiDAS as a potential therapeutic vulnerability. $\textit{Full-text embargoed until: 2027-03-18}$
2026-04-15 | A dual role for cGAS in shaping cellular and organismal responses to genomic instability.
Mutations in DNA damage repair (DDR) genes lead to genomic instability, driving a range of degenerative syndromes. In addition to promoting mutation accumulation, unrepaired DNA damage can leak into the cytosol and activate innate immune-sensing pathways, particularly the cGAS-STING axis. However, the extent to which cGAS causally contributes to organismal pathology in DDR syndromes in vivo remains unresolved. Here, we genetically model ataxia telangiectasia (A-T) and Bloom syndrome in the short-lived turquoise killifish (Nothobranchius furzeri) and demonstrate that genetic disruption of cgas in the A-T model partially ameliorates germline failure, hepatic senescence, and cerebellar neuroinflammation. Unexpectedly, cgas loss also reversed cellular hallmarks of genome instability, including reduced micronuclei, improved telomere integrity, and restored H3K9me3-marked heterochromatin landscape, consistent with STING-independent nuclear functions of cGAS that influence DNA repair and chromatin. Together, these data identify cGAS as a context-dependent amplifier of DDR pathology acting through canonical inflammatory signaling and noncanonical nuclear mechanisms that shape genome stability. Accordingly, our findings support pharmacological cGAS inhibition as a potential strategy for DDR syndromes in settings of chronic DNA damage while highlighting that cgas loss in an otherwise naive background exacerbates pathology and genomic instability, underscoring its essential role in normal physiology.
proteins
2025-02-25 | Phosphorylated BLM peptide acts as an agonist for DNA damage response.
Upon exposure to ionizing irradiation, the MRE11-RAD50-NBS1 complex potentiates the recruitment of ATM (ataxia-telangiectasia mutated) kinase to the double-strand breaks. We show that the lack of BLM causes a decrease in the autophosphorylation of ATM in mice mammary glands, which have lost one or both copies of BLM. In isogenic human cells, the DNA damage response (DDR) pathway was dampened in the absence of BLM, which negatively affected the recruitment of DDR factors onto the chromatin, thereby indicating a direct role of BLM in augmenting DDR. Mechanistically, this was due to the BLM-dependent dissociation of inactive ATM dimers into active monomers. Fragmentation analysis of BLM followed by kinase assays revealed a 20-mer BLM peptide (91-110 aa), sufficient to enhance ATM-dependent p53 phosphorylation. ATM-mediated phosphorylation of BLM at Thr99 within BLM (91-110) peptide enhanced ATM kinase activity due to its interaction with NBS1 and causing ATM monomerization. Delivery of phosphomimetic T99E counterpart of BLM (91-110 aa) peptide led to ATM activation followed by restoration of the DDR even in the absence of ionizing irradiation (both in cells and in BLM knockout mice), indicating its role as a DDR agonist, which can be potentially used to prevent the initiation of neoplastic transformation.
2025-01-15 | Synergistic protection of nascent DNA at stalled forks by MSANTD4 and BRCA1/2-RAD51.
The regressed arms of reversed replication forks exhibit structural similarities to one-ended double-stranded breaks and need to be protected against uncontrolled nucleolytic degradation. Here, we identify MSANTD4 (Myb/SANT-like DNA-binding domain-containing protein 4), a functionally uncharacterized protein that uniquely counters the replication protein A (RPA)-Bloom (BLM)/Werner syndrome helicase (WRN)-DNA replication helicase/nuclease 2 (DNA2) complex to safeguard reversed replication forks from detrimental degradation, independently of the breast cancer susceptibility proteins (BRCA1/2)-DNA repair protein RAD51 pathway. MSANTD4 specifically interacts with the junctions between single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in DNA substrates harboring a 3' overhang, which resemble the structural features of regressed arms processed by WRN-DNA2. This DNA-binding capability allows MSANTD4 to accumulate at reversed forks, strategically antagonizing the RPA-BLM/WRN-DNA2 complex by impeding its access to the ssDNA-dsDNA junction of the regressed arms. Loss of MSANTD4 exacerbates genome instability induced by replication stress in BRCA1/2-deficient cells. Our findings unveil a collaborative defense mechanism orchestrated by MSANTD4 and BRCA1/2-RAD51, effectively counteracting nucleolytic attacks on the regressed arms and synergistically preserving the integrity of reversed forks.
2023-10-12 | Modified iPOND revealed the role of mutant p53 in promoting helicase function and telomere maintenance
The G-rich DNA, such as telomere, tends to form G-quadruplex (G4) structure, which slows down the replication fork progression, induces replication stress, and becomes the chromosome fragile sites.Here we described a molecular strategy that cells developed to overcome the DNA replication stress via DNA helicase regulation.The p53N236S (p53S) mutation has been found in the Werner syndrome mouse embryo fibroblast (MEFs) escaped from senescence, could be the driving force for cell escaping senescence.We revealed that the p53S could transcriptionally up-regulate DNA helicases expression, including Wrn, Blm, Timeless, Ddx, Mcm, Gins, Fanc, as well as telomere specific proteins Terf1, Pot1, through which p53S promoted the unwinding of G4 structures, and protected the cells from DNA replication stress induced by G4 stabilizer.By modified iPOND (isolation of proteins on nascent DNA) assay and telomere assay, we demonstrated that the p53S could promote the recruitment of those helicases to the DNA replication forks, facilitated the maintenance of telomere, and prevent the telomere dysfunction induced by G4 stabilizer.Interestingly, we did not observe the function of promoting G4 resolving and facilitating telomere lengthening in the cells with Li-Fraumeni Syndrome mutation-p53R172H (p53H), which suggests that this is the specific gain of function for p53S.Together our data suggest that the p53S could gain the new function of releasing the replication stress via regulating the helicase function and G4 structure, which benefits telomere lengthening.This strategy could be applied to the treatment of diseases caused by telomere replication stress.
2023-03-30 | Data from BLM Helicase Facilitates Mus81 Endonuclease Activity in Human Cells
<div>Abstract<p>Bloom syndrome is a rare, autosomal recessive inherited disorder in humans. The product of the Bloom syndrome mutated gene, designated BLM, is a member of the RecQ helicase family. BLM has been proposed to function at the interface of replication and recombination, and to facilitate the repair of DNA damage. Here, we report <i>in vivo</i> physical interaction and colocalization of BLM and a DNA structure–specific endonuclease, Mus81, at sites of stalled replication forks outside the promyelocytic leukemia nuclear bodies during the S-phase arrest of the cell cycle. Amino acids 125 to 244 of Mus81 interact with the C-terminal region (amino acids 1,007-1,417) of BLM. Whereas Mus81 does not have any effect on the helicase activity of BLM, BLM can stimulate Mus81 endonuclease activity on the nicked Holliday junctions and 3′ flap. This stimulation is due to enhanced binding of Mus81 to the DNA substrates. These data suggest a new function of BLM in cooperating with Mus81 during processing and restoration of stalled replication forks.</p></div>
2023-03-27 | KNO1‐mediated autophagic degradation of the Bloom syndrome complex component RMI1 promotes homologous recombination
Abstract Homologous recombination (HR) is a key DNA damage repair pathway that is tightly adjusted to the state of a cell. A central regulator of homologous recombination is the conserved helicase‐containing Bloom syndrome complex, renowned for its crucial role in maintaining genome integrity. Here, we show that in Arabidopsis thaliana , Bloom complex activity is controlled by selective autophagy. We find that the recently identified DNA damage regulator KNO1 facilitates K63‐linked ubiquitination of RMI1, a structural component of the complex, thereby triggering RMI1 autophagic degradation and resulting in increased homologous recombination. Conversely, reduced autophagic activity makes plants hypersensitive to DNA damage. KNO1 itself is also controlled at the level of proteolysis, in this case mediated by the ubiquitin–proteasome system, becoming stabilized upon DNA damage via two redundantly acting deubiquitinases, UBP12 and UBP13. These findings uncover a regulatory cascade of selective and interconnected protein degradation steps resulting in a fine‐tuned HR response upon DNA damage.
gene therapies
2026-06-24 | Early-Onset Colorectal and Gastric Adenocarcinomas in a Patient With a Heterozygous BLM p.E1317K Variant of Uncertain Significance
Early-onset gastrointestinal malignancies may raise concerns for hereditary cancer susceptibility, although interpretation of rare germline variants identified through multigene testing remains challenging. We describe the case of a male patient diagnosed with stage IIIB mismatch repair-proficient sigmoid adenocarcinoma at age 29 who subsequently developed a poorly differentiated gastric adenocarcinoma five years later. Germline testing identified a heterozygous BLM p.E1317K variant of uncertain significance (VUS) and no other pathogenic germline alterations. Both tumors demonstrated microsatellite-stable, mismatch repair-proficient disease with low tumor mutational burden, and the patient’s family history was notable for gastric cancer in his father, collectively raising concern for an underlying cancer predisposition. Although Bloom syndrome is associated with biallelic pathogenic BLM variants, the oncologic significance of heterozygous BLM alterations remains incompletely defined. This report highlights the interpretive challenges surrounding rare germline variants in patients with multiple early-onset gastrointestinal malignancies and underscores the need for further investigation into the potential role of selected heterozygous BLM variants in cancer susceptibility.
2025-11-08 | The Relationship Between Insulin Resistance and Cancer in Humans.
An independent association between insulin resistance and cancer has been consistently reported in humans. Patients with cancer display insulin resistance or its clinical manifestations, and this metabolic adaptation precedes the clinical diagnosis of cancer. Insulin resistance in cancer patients is associated with a metabolic switch from oxidative metabolism toward glycolysis that spares oxygen to be used in anabolic processes and facilitates the fast production of energy and intermediate metabolites required for the rapid proliferation of cancer cells. In malignant cells, glucose consumption via glycolysis occurs under normoxic conditions (aerobic glycolysis). Pathogenic mechanisms underlying insulin resistance in cancer patients include hypoxia-inducible factor-1 upregulation and overproduction of cytokines, such as interferon, interleukin-6, interleukin-18, and interleukin-1β. Deficit of 2-oxoglutarate (α-ketoglutarate) has been detected in cancer cells and may facilitate hypoxia-inducible factor-1 assembly and activity. Overproduction of cytokines in cancer patients follows activation of the immune system by abnormal nucleic acid variants. Anomalous DNA or RNA structures are recognized by immune sensors and stimulate signaling pathways that ultimately increase cytokine production. Likewise, interferon overproduction occurs in congenital disorders that feature ineffectively repaired DNA lesions, such as Werner syndrome, Bloom syndrome, mutations in DNA polymerase-δ1, and ataxia telangiectasia. These diseases cause simultaneous insulin resistance and a high tendency to develop cancer, highlighting the relationship between the two processes. Defectively repaired DNA injury endangers genomic integrity, predisposing to cancer, and activates the immune system to increase interferon production and subsequent insulin resistance. Hypoxia-inducible factor-1 and cytokines induce insulin resistance by suppressing peroxisome proliferator-activated-γ in the subcutaneous adipose tissue.
2025-09-01 | The First Report on BLM Gene Mutations in Iranian Patients with Different Phenotypes of Bloom Syndrome: Identifying Two Mutations and a Literature Review on BLM Gene Mutations
Bloom syndrome (BS), also called congenital telangiectatic erythema, is a rare autosomal recessive inherited disorder characterized by genomic instability and predisposition to the development of all types of cancer. Besides, additional presentations have been observed in BS. Herein, we investigated the clinical and genetic aspects ofeight patients withBS in three unrelated Iranian families that exhibit less common symptoms like intellectual disability and polydactyly. After the thorough clinical examinations, whole-exome sequencing (WES) was performed. Following the detection of candidate variants, the familialco-segregation analysis was carried out by PCR-based Sanger sequencing. Meanwhile, a literature review was carried out by utilizing databases to compile information on BLM gene mutations from 2007 to the present. We identified two pathogenic nonsense mutations in the BLM gene in the studied families with the homozygous state. The first one, c.3415C>T (p.Arg1139Ter) mutation, was detected in the 5 patients from family 1 and one patient from family 3. The second one was c.2695C>T (p.Arg899Ter) mutation identified in the two patients from family 2. All unaffected parents were identified with the heterozygous state for the detected mutations in their affected offspring. Through our research in various articles, we gathered twelve different mutations in 17 BS patients from 2007 to the present. Mutation identification and presenting clinical manifestation of the rare disorder make it much easier and faster to diagnose this syndrome from other similar disorders. It also helps with carrier detection, as well as, prenatal diagnosis of bloom syndrome in high-risk families.
2025-03-01 | Establishment of Preclinical Trial of Lentiviral Gene Transfer to Prevent Bloom Syndrome-Related Hematological Malignancy
Bloom syndrome is a rare hereditary DNA repair disorder associated with a high risk of cancer. Patients with Bloom syndrome have a markedly increased risk of developing various cancers, particularly hematological malignancies, making cancer the leading cause of death in these individuals. Therefore, we hypothesized that the prevention of cancer could be a key point for these patients. This review focuses on designing a preclinical study exploring the potential of gene therapy to address this significant clinical challenge. Three issues were established for this preclinical study, and research is ongoing to solve these issues. The first was the development of an envelope-modified lentivirus designed to treat DNA repair disorders. This lentivirus has been engineered to effectively deliver therapeutic genes to cells affected by Bloom syndrome, and cytokine stimulation induces apoptosis in hematopoietic stem cells (HSCs). Second, we demonstrated that lentivirus-mediated gene transfer corrects the expression and function of BLM gene in bone marrow cells derived from a Bloom syndrome mouse model. These experiments indicated that the therapeutic gene delivered by the lentivirus can correct cellular defects associated with Bloom syndrome, thereby restoring normal cell function. Finally, we investigated the ability of gene therapy to prevent the development of radiation-induced tumors in BLM mice. By detailing the development and testing of this innovative gene therapy, this review demonstrated the potential of such treatments to transform the clinical management of DNA repair disorders, which could be translated into improved survival and quality of life in patients with Bloom syndrome.
2023-03-01 | Protocol for a high titer of BaEV-Rless pseudotyped lentiviral vector: Focus on syncytium formation and detachment.
The development of hematopoietic stem cell (HSCs) gene therapy for DNA repair disorders, such as Fanconi anemia and Bloom syndrome, is challenging because of the induction of HSCs apoptosis by cytokine stimulation. Although the Baboon envelope pseudotyped lentiviral vector (BaEV-Rless-LV) has been reported as a non-stimulatory gene transfer tool, the virus titer of BaEV-Rless-LV is too low for use in clinical applications. Transfected 293 T cells with helper plasmids, including the BaEV-Rless plasmid, showed morphological changes, such as syncytium formation and detachment. To establish a novel protocol for producing a high titer of BaEV-Rless-LV, we optimized three aspects of a basic virus production protocol by focusing on modifying culture conditions and the use of reagents: the virus titer increased 3-fold when the amount of BaEV-Rless plasmid was increased 1.2-fold; the highest titer was obtained when the viral supernatant was harvested at 48-h post-transfection, despite complete syncytium formation and detachment of the 293 T cells; and the use of poly-L-lysine-coated culture plates to enhance the adhesion and proliferation of 293 T cells and prevent detachment doubled the titer. Collectively, our novel protocol resulted in a 10-fold titer increase compared to the basic protocol and may be useful in clinical applications for treating DNA repair disorders.
other
2025-02-18 | BLM knockdown promotes cells autophagy via p53-AMPK-mTOR pathway in triple negative breast cancer cells.
This study investigated the function of the Bloom syndrome RecQ helicase-like gene (BLM) in triple-negative breast cancer (TNBC). The expression levels of BLM in breast cancer cells were assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemical analysis. Cell proliferation, apoptosis, migration, and invasion were evaluated using the CCK-8 assay, clonogenic assay, flow cytometry, wound healing assay, and Transwell assay, respectively. Autophagosomes were observed via transmission electron microscopy (TEM). The expression levels of LC3B, Beclin1, and p62 were also measured. A murine xenograft model was employed to examine the impact of BLM on TNBC tumor growth, with tumor weight and volume recorded. Hematoxylin and eosin (H&E) staining and immunohistochemistry were utilized to assess pathological changes and Ki67 expression in tumor tissues. Additionally, Western blotting analysis was conducted to determine the expression of p53, AMPK, phosphorylated AMPK (p-AMPK), mTOR, and phosphorylated mTOR (p-mTOR). The expression of BLM was elevated in BT549 cells compared to normal cells. Following BLM knockdown, BT549 cell proliferation was significantly reduced, while apoptosis was enhanced. The migration rate of cells in the siBLM group was markedly decreased, as were the invasion and metastasis rates. TEM results indicated an increased presence of autophagosomes in the siBLM group, with significantly elevated expression levels of LC3B and Beclin1, and a decreased expression level of p62. Tumor volume and weight in the shBLM group were significantly lower than those in the shCtrl group. The number of intratumoral cells decreased, with most exhibiting nucleolysis or disintegration. Ki67 expression in the tumor tissue was also notably reduced. Additionally, the expression levels of p-mTOR, p-AMPK, and P53 proteins in the shBLM group were decreased. The knockdown of BLM significantly inhibited cell proliferation, migration, and invasion, while promoting apoptosis. This effect may be mediated through the regulation of the p53-AMPK-mTOR pathway.
2008-04-02 | Competition between the DNA unwinding and strand pairing activities of the Werner and Bloom syndrome proteins.
The premature aging and cancer-prone Werner and Bloom syndromes are caused by defects in the RecQ helicase enzymes WRN and BLM, respectively. Recently, both WRN and BLM (as well as several other RecQ members) have been shown to possess a strand annealing activity in addition to the requisite DNA unwinding activity. Since an annealing function would appear to directly oppose the action of a helicase, we have examined in this study the dynamic equilibrium between unwinding and annealing mediated by either WRN or BLM. Our investigation into the competition between annealing and unwinding demonstrates that, under standard reaction conditions, WRN- or BLM-mediated annealing can partially or completely mask unwinding as measured in standard helicase assays. Several strategies were employed to suppress the annealing activity so that the actual strength of WRN- or BLM-dependent unwinding could be more accurately assessed. Interestingly, if a DNA oligomer complementary to one strand of the DNA substrate to be unwound is added during the helicase reaction, both WRN and BLM unwinding is enhanced, presumably by preventing protein-mediated re-annealing. This strategy allowed measurement of WRN-catalyzed unwinding of long (80 base pair) duplex regions and fully complementary, blunt-ended duplexes, both of which were otherwise quite refractory to the helicase activity of WRN. Similarly, the addition of trap strand stimulated the ability of BLM to unwind long and blunt-ended duplexes. The stimulatory effect of the human replication protein A (hRPA, the eukaryotic single-stranded DNA binding protein) on both WRN- and BLM-dependent unwinding was also re-examined in light of its possible role in preventing re-annealing. Our results show that hRPA influences the outcome of WRN and BLM helicase assays by both inhibiting re-annealing and directly promoting unwinding, with the larger contribution from the latter mechanism. These findings indicate that measurements of unwinding by WRN, BLM, and probably other RecQ helicases are complicated by their annealing properties. Thus, WRN- and BLM-dependent unwinding activities are significantly stronger than previously believed. Since this broadens the range of potential physiological substrates for WRN and BLM, our findings have relevance for understanding their functions in vitro and in vivo.
2006-02-07 | Enhanced gene targeting efficiency by siRNA that silences the expression of the Bloom syndrome gene in human cells
Gene targeting via homologous recombination is a powerful tool for studying gene function, but the targeting efficiency in human cell lines is too low for generating knockout mutants. Several cell lines null for the gene responsible for Bloom syndrome, BLM , have shown elevated targeting efficiencies. Therefore, we reasoned that gene targeting would be enhanced by transient suppression of BLM expression by RNA interference. To test this, we constructed a gene correction assay system to measure gene targeting frequencies using a disrupted hypoxanthine phosphoribosyltransferase ( HPRT ) locus in the human HT1080 cell line, and examined the effect of small interfering RNA (siRNA) for BLM on gene targeting. When HPRT ‐null cells pretreated with BLM siRNA were co‐transfected with the siRNA and a gene correction vector, the gene targeting frequency was elevated three‐fold, while the random integration frequency was marginally affected. Remarkably, in BLM heterozygous (+/–) cells derived from HPRT ‐null cells, the BLM siRNA treatment gave more than five‐fold higher targeting frequencies, even with one‐tenth the amount of BLM siRNA used for BLM +/+ cells. Furthermore, in the human pre‐B cell line Nalm‐6, the siRNA treatment enhanced gene targeting 6.3‐fold and > 5.8‐fold at the HPRT and adenine phosphoribosyltransferase ( APRT ) loci, respectively. These results indicate that transient suppression of BLM expression by siRNA stimulates gene targeting in human cells, facilitating a further improvement of gene targeting protocols for human cell lines.
2005-06-28 | BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.
Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLM(Cin/+), transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.